Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life ‘LIver Network Activity’ (LINA) cohort update results-Reference-Cited by-同舟云学术

Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life ‘LIver Network Activity’ (LINA) cohort update results

Published:2021-03-02 Issue:9 Volume:15 Page:1057-1063
ISSN:1747-4124
Container-title:Expert Review of Gastroenterology & Hepatology
language:en
Short-container-title:Expert Review of Gastroenterology & Hepatology

Author:

Scotto Riccardo¹,Buonomo Antonio Riccardo¹,De Pascalis Stefania²,Nerilli Mariagiovanna¹,Pinchera Biagio¹,Staiano Laura³,Mercinelli Simona¹,Cattaneo Letizia¹,Stanzione Maria²,Stornaiuolo Gianfranca²,Martini Salvatore²,Messina Vincenzo⁴,Coppola Carmine³,Coppola Nicola²,Gentile Ivan¹

Affiliation:

1. Department of Clinical Medicine and Surgery – Section of Infectious Diseases, University of Naples Federico II, Naples, Italy

2. University of Campania Luigi Vanvitelli, Italy

3. Department of Internal Medicine - Unit of Hepatology and Interventional Ultrasonography, OORR Area Stabiese Plesso Nuovo Gragnano, Naples, Italy

4. Infectious Diseases Unit, A.O. Caserta, Caserta, Italy

Publisher

Informa UK Limited

Subject

Gastroenterology,Hepatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474124.2021.1890029

Reference46 articles.

1. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial

2. Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

3. Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

4. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

5. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus